间充质干细胞及其外泌体与Th17/Treg对银屑病发病机制的研究进展

doi:10.35541/cjd.20190012

Abstract

Abstract: 【Abstract】 T helper 17 （Th17） cell /regulatory T （Treg）cell imbalance has been widely considered as one of immunopathogeneses of psoriasis. Mesenchymal stem cells （MSC） can inhibit the proliferation and differentiation of Th17 cells, but induce the proliferation of Treg cells. Exosomes secreted by MSC are a kind of important carrier for intercellular communication and material transportation. Studies have found that exosomes from MSC and MSC have similar immunoregulatory function, which can inhibit the proliferation of Th17 cells and induce the differentiation of Treg cells. In recent years, many studies have shown that abnormalities of MSC in bone marrow and skin lesions of psoriasis patients are related to the occurrence of psoriasis, but the mechanism is still unclear. This review elaborates the role of normal MSC and their exosomes in the maintenance of Th17/Treg balance, which provides ideas for studying how abnormalities of MSC in bone marrow and skin lesions of psoriasis patients participate in the occurrence of psoriasis.

Key words: Psoriasis, Mesenchymal stem cells, Exosomes, Th17 cells, T-lymphocytes, regulatory

Han Qixin, Niu Xuping, Liu Jia, Qi Ruiqun, Wu Yan. Role of mesenchymal stem cells and their exosomes in Th17/Treg-related pathogenesis of psoriasis[J]. Chinese Journal of Dermatology, 2020, 53(2): 151-154.doi:10.35541/cjd.20190012

References ［40］

［1］	Fierabracci A, Del Fattore A, Luciano R, et al. Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles［J］. Cell Transplant, 2015,24（2）:133⁃149. doi: 10. 3727/096368913X675728.
［2］	Zhang B, Yeo R, Lai RC, et al. Mesenchymal stromal cell exosome⁃enhanced regulatory T⁃cell production through an antigen⁃presenting cell⁃mediated pathway［J］. Cytotherapy, 2018,20（5）:687⁃696. doi: 10.1016/j.jcyt.2018.02.372.
［3］	Keating A. Mesenchymal stromal cells: new directions［J］. Cell Stem Cell, 2012,10（6）:709⁃716. doi: 10.1016/j.stem.2012.05.015.
［4］	Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses［J］. Blood, 2005,105（4）:1815⁃1822. doi: 10.1182/blood⁃2004⁃04⁃1559.
［5］	Du YM, Zhuansun YX, Chen R, et al. Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma［J］. Exp Cell Res, 2018,363（1）:114⁃120. doi: 10.1016/j.yexcr.2017.12.021.
［6］	Zhang Q, Fu L, Liang Y, et al. Exosomes originating from MSCs stimulated with TGF⁃β and IFN⁃γ promote Treg differentiation［J］. J Cell Physiol, 2018,233（9）:6832⁃6840. doi: 10.1002/jcp. 26436.
［7］	Zhang K, Liu R, Yin G, et al. Differential cytokine secretion of cultured bone marrow stromal cells from patients with psoriasis and healthy volunteers［J］. Eur J Dermatol, 2010,20（1）:49⁃53. doi: 10.1684/ejd.2010.0845.
［8］	刘瑞风, 杨元文, 赵新程, 等. 银屑病患者皮损间充质干细胞分泌表皮生长因子、干细胞因子、碱性成纤维细胞生长因子、血管内皮生长因子水平检测［J］. 中国免疫学杂志, 2013,29（10）:1046⁃1049,1063. doi: 10.3969/j.issn.1000⁃484X.2013.10. 008.
［9］	赵新程, 梁见楠, 杨晓红, 等. 银屑病患者真皮间充质干细胞中细胞因子受体因子-1白细胞介素-6水平的变化及意义［J］. 中国药物与临床, 2018,18（4）:505⁃508. doi: 10.11655/zgywylc 2018.04.001.
［10］	Li J, Hou R, Niu X, et al. Comparison of microarray and RNA⁃Seq analysis of mRNA expression in dermal mesenchymal stem cells［J］. Biotechnol Lett, 2016,38（1）:33⁃41. doi: 10.1007/s10529⁃015⁃1963⁃5.
［11］	Niu X, Chang W, Liu R, et al. Expression of pro⁃angiogenic genes in mesenchymal stem cells derived from dermis of patients with psoriasis［J］. Int J Dermatol, 2016,55（5）:e280⁃e288. doi: 10.1111/ijd.13197.
［12］	Kotb IS, Lewis BJ, Barker RN, et al. Differential effects of phototherapy, adalimumab and betamethasone⁃calcipotriol on effector and regulatory T cells in psoriasis［J］. Br J Dermatol, 2018,179（1）:127⁃135. doi: 10.1111/bjd.16336.
［13］	Li T, Gu M, Liu P, et al. Clinical significance of decreased interleukin⁃35 expression in patients with psoriasis［J］. Microbiol Immunol, 2018,62（7）:454⁃461. doi: 10.1111/1348⁃0421.12605.
［14］	Mak RK, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis［J］. Actas Dermosifiliogr, 2009,100（Suppl 2）:2⁃13.
［15］	Guttman⁃Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment［J］. Exp Dermatol, 2018,27（4）:409⁃417. doi: 10. 1111/exd.13336.
［16］	Wawrzycki B, Pietrzak A, Grywalska E, et al. Interleukin⁃22 and its correlation with disease activity in plaque psoriasis［J］. Arch Immunol Ther Exp （Warsz）, 2019,67（2）:103⁃108. doi: 10.1007/s00005⁃018⁃0527⁃5.
［17］	Owczarczyk⁃Saczonek A, Czerwińska J, Placek W. The role of regulatory T cells and anti⁃inflammatory cytokines in psoriasis［J］. Acta Dermatovenerol Alp Pannonica Adriat, 2018,27（1）:17⁃23.
［18］	Tedgui A, Mallat Z. Interleukin⁃10: an anti⁃atherogenic cytokine［J］. Pathol Biol （Paris）, 2001,49（2）:107⁃108.
［19］	Döcke WD, Asadullah K, Belbe G, et al. Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time⁃dependent, and persisting immune effects of interleukin⁃10 application in psoriasis［J］. J Leukoc Biol, 2009,85（3）:582⁃593. doi: 10.1189/jlb.0408249.
［20］	Gu Y, Yang J, Ouyang X, et al. Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells［J］. Eur J Immunol, 2008,38（7）:1807⁃1813. doi: 10.1002/eji.200838331.
［21］	Cassis L, Aiello S, Noris M. Natural versus adaptive regulatory T cells［J］. Contrib Nephrol, 2005,146:121⁃131. doi: 10.1159/0000 82072.
［22］	Galgani M, De Rosa V, La Cava A, et al. Role of metabolism in the immunobiology of regulatory T cells［J］. J Immunol, 2016,197（7）:2567⁃2575. doi: 10.4049/jimmunol.1600242.
［23］	Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation［J］. J Immunol, 2005,174（1）:164⁃173. doi: 10.4049/ jimmunol.174.1.164.
［24］	Ke F, Zhang L, Liu Z, et al. Autocrine interleukin⁃6 drives skin⁃derived mesenchymal stem cell trafficking via regulating voltage⁃gated Ca2+ channels［J］. Stem Cells, 2014,32（10）:2799⁃2810. doi: 10.1002/stem.1763.
［25］	Park M, Kim YH, Ryu JH, et al. Corrigendum to "Immune suppressive effects of tonsil⁃derived mesenchymal stem cells on mouse bone⁃marrow⁃derived dendritic cells"［J］. Stem Cells Int, 2019,2019:9071046. doi: 10.1155/2019/9071046.
［26］	Kim JY, Park M, Kim YH, et al. Tonsil⁃derived mesenchymal stem cells （T⁃MSCs） prevent Th17⁃mediated autoimmune response via regulation of the programmed death⁃1/programmed death ligand⁃1 （PD⁃1/PD⁃L1） pathway［J］. J Tissue Eng Regen Med, 2018,12（2）:e1022⁃e1033. doi: 10.1002/term.2423.
［27］	Hou R, Yan H, Niu X, et al. Gene expression profile of dermal mesenchymal stem cells from patients with psoriasis［J］. J Eur Acad Dermatol Venereol, 2014,28（12）:1782⁃1791. doi: 10.1111/ jdv.12420.
［28］	Milosavljevic N, Gazdic M, Simovic Markovic B, et al. Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells ⁃ an experimental study［J］. Transpl Int, 2018,31（1）:102⁃115. doi: 10.1111/tri.13023.
［29］	Li X, Sun W, Xi W, et al. Transplantation of skin mesenchymal stem cells attenuated AngII⁃induced hypertension and vascular injury［J］. Biochem Biophys Res Commun, 2018,497（4）:1068⁃1075. doi: 10.1016/j.bbrc.2018.02.180.
［30］	Kim CH, Lim CY, Lee JH, et al. Human embryonic stem cells⁃derived mesenchymal stem cells reduce the symptom of psoriasis in imiquimod⁃induced skin model［J］. Tissue Eng Regen Med, 2019,16（1）:93⁃102. doi: 10.1007/s13770⁃018⁃0165⁃3.
［31］	Campanati A, Orciani M, Consales V, et al. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1⁃Th17/Th2 imbalance of psoriasis［J］. Arch Dermatol Res, 2014,306（10）:915⁃920. doi: 10.1007/s00403⁃ 014⁃1493⁃3.
［32］	Chen W, Huang Y, Han J, et al. Immunomodulatory effects of mesenchymal stromal cells⁃derived exosome［J］. Immunol Res, 2016,64（4）:831⁃840. doi: 10.1007/s12026⁃016⁃8798⁃6.
［33］	Tasso R, Ilengo C, Quarto R, et al. Mesenchymal stem cells induce functionally active T⁃regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis［J］. Invest Ophthalmol Vis Sci, 2012,53（2）:786⁃793. doi: 10.1167/iovs.11⁃8211.
［34］	Gonzalez⁃Rey E, Gonzalez MA, Varela N, et al. Human adipose⁃derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis［J］. Ann Rheum Dis, 2010,69（1）:241⁃248. doi: 10.1136/ard.2008.101881.
［35］	Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles［J］. Nat Rev Immunol, 2014,14（3）:195⁃208. doi: 10.1038/nri3622.
［36］	Blazquez R, Sanchez⁃Margallo FM, de la Rosa O, et al. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells［J］. Front Immunol, 2014,5:556. doi: 10.3389/fimmu.2014.00556.
［37］	Zhang B, Yin Y, Lai RC, et al. Immunotherapeutic potential of extracellular vesicles［J］. Front Immunol, 2014,5:518. doi: 10.3389/fimmu.2014.00518.
［38］	Ohno S, Ishikawa A, Kuroda M. Roles of exosomes and microvesicles in disease pathogenesis［J］. Adv Drug Deliv Rev, 2013,65（3）:398⁃401. doi: 10.1016/j.addr.2012.07.019.
［39］	Cosenza S, Toupet K, Maumus M, et al. Mesenchymal stem cells⁃derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis［J］. Theranostics, 2018,8（5）:1399⁃1410. doi: 10.7150/thno.21072.
［40］	Burr SP, Dazzi F, Garden OA. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance?［J］. Immunol Cell Biol, 2013,91（1）:12⁃18. doi: 10.1038/icb.2012.60.

[1]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848.
[2]	Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844.
[3]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.
[4]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[5]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[6]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[7]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[8]	China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401.
[9]	Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360.
[10]	Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368.
[11]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[12]	Ruan Shifan, Zhang Peng, Lin Tingting, Luo Renwei, Bao Siyi, Xue Chenyao, Tong Zequn, Zhang Liangliang, Gong Ting, Ji Chao, . Correlations between psoriasis vulgaris and dyslipidemia [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220322-e20220322.
[13]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[14]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[15]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.

Role of mesenchymal stem cells and their exosomes in Th17/Treg-related pathogenesis of psoriasis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［40］

Related Articles 15

Metrics

Comments

Recommended 10